Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms

• Status: Terminated
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if a single dose of pregabalin 300mg in patients receiving medications for sedative-hypnotic withdrawal symptoms will produce meaningful differences in measures of "drug liking" and "drug high" as compared to placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre for Addiction and Mental Health
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Admitted to the Medical Withdrawal Unit at the Centre for Addiction and Mental Health for medically assisted withdrawal from benzodiazepines, zopiclone and/or zolpidem

• Willing and capable to give written informed consent

Exclusion Criteria:

• Patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

• Pregnant or nursing women

• Renal impairment (creatinine clearance less than 60ml/min)

• History of angioedema, or taking drugs associated with angioedema (e.g., ACE-inhibitors).

• Currently taking pregabalin or gabapentin

• Currently taking thiazolidinedione antidiabetic agents (e.g., rosiglitazone, pioglitazone)

• Previous history of pregabalin or gabapentin abuse